叮当健康旗下叮当快药凭借多年药学服务实践，与国药控股、首都医科大学附属北京安贞医院、宣武医 院、复旦大学药学院、北京大学药学院等机构共同成为该标准核心起草单位。 近日，T/CAPC 021—2026《零售药店专科药师药学服务能力评价指南》团体标准正式发布，这是我国 零售药店领域首部针对专科药师药学服务能力的系统性评价文件，填补了行业标准空白。 据了解，该标准明确了专科药师资质、职责、知识、技能及素养五大维度，构建了处方调剂、用药咨 询、用药评估、随访、药历、宣教、药物警戒等全流程药学服务能力评价体系。叮当快药依托多年来 7*24小时在线药学服务、处方审核、用药随访等药师服务的实践经验，为药师用药评估、风险防范等药 师核心能力要求提供了参考依据。 业内人士认为，该标准发布标志着零售药店向"专业化健康服务终端"转型迈出关键一步，通过能力进阶 路径与评价工具，推动药店人才梯队建设与服务分级，提升慢病管理、特殊人群用药等专业能力，助力 分级诊疗改革。 作为起草单位之一，叮当快药始终以药师专业能力为核心战略，依托线上线下一体化模式，构建起专业 药师团队，7×24小时为提供用户提供在线用药咨询、处方审核、慢病随访等全周期 ...

A股三大指数早盘涨跌不一，截至午盘，沪指涨0.27%，深成指涨0.24%，创业板指跌0.17%，北证50指数涨3.36%，沪深京 三市半日成交额19136亿元，较上日放量1239亿元。全市场超3500只个股上涨。 板块题材上，光伏设备、贵金属、商业航天、医药商业、A应用、赛马、电池板块涨幅居前；保险、煤炭开采加工、半导 体、银行、页岩气板块跌幅居前。盘面上，商业航天、太空光伏方向集体大涨，巨力索具3连板，中超控股、钧达股份、西部 材料2连板，此前马斯克明确力挺太空光伏，并披露关键产能规划。零售药店兼并重组获政策支持，药店板块表现出色，人民 同泰、益丰药房双双封板。国际金价逼近5000美元，黄金股再度大涨，白银有色录得4连板。此外，AI应用、电池、化工板块 盘中均有异动。另一方面，部分算力硬件股回调，新易盛盘中跌超6%，天孚通信、中际旭创、工业富联跟跌。盘中多只宽基 ETF成交额放大，三大指数有所承压。 ...

Core Viewpoint - The Ministry of Commerce and nine other departments have jointly issued opinions to promote high-quality development in the pharmaceutical retail industry, focusing on five key measures [1]. Group 1: Key Measures - The five key measures include improving pharmaceutical services, innovating health services, strengthening emergency services, optimizing industry structure, and regulating industry order [1]. Group 2: Industry Structure Optimization - The opinions support the merger and reorganization of retail pharmacies, encouraging horizontal mergers and acquisitions among pharmaceutical retail enterprises [1]. - Local governments are encouraged to optimize the business environment, particularly for integrated chain or standalone pharmacies, by streamlining the application process for pharmaceutical business licenses [1]. - For changes in medical insurance qualifications, the original qualifications are allowed to continue and be used until the new qualifications are officially opened, at which point the original qualifications can be canceled [1]. Group 3: Industry Transformation - The pharmaceutical retail industry in China is at a critical stage of innovative transformation, requiring a shift from traditional drug sales to comprehensive health services, enhancing professional services, health promotion, and emergency supply capabilities [1].

Aerospace - Beijing Chuanqiu Space Technology Co., Ltd. held a global launch event for space tourism, showcasing the first commercial manned spacecraft "Chuanqiu No. 1 (CYZ1)" with over 20 space tourists already booked, aiming for its first manned flight in 2028 [1] - SpaceX plans to launch its second-generation Starlink system in 2027, which is expected to provide internet services with over 100 times the capacity and more than 20 times the throughput compared to the first generation [1] - The aerospace sector is transitioning from a "cost center" driven by national will to a "growth engine" driven by commercial demand, with significant growth potential in the trillion-dollar market [1] Solid-State Batteries - A123 announced a product launch event for its new series of semi-solid state energy storage products, including the "Xingchen" series semi-solid state cells and "Xinghe" series energy storage systems, scheduled for January 23, 2026 [2] - The new semi-solid state batteries significantly enhance safety and environmental adaptability, achieving excellent safety performance in extreme conditions, which could reduce the risk of electric vehicle fires [2] Retail Pharmacy - The Ministry of Commerce and nine other departments released opinions to promote high-quality development in the retail pharmacy industry, supporting mergers and acquisitions among retail pharmacies [3] - The retail pharmacy sector is expected to accelerate consolidation by 2025, with a projected decrease in the total number of pharmacies, concentrating customer traffic towards leading players [3] Passive Components - Passive component manufacturer Huaxinke announced a price increase for all chip resistor products starting February 1, with expected price hikes of around 20% [4] - The passive components industry is experiencing a price surge, with structural price increases observed across various products, driven by high demand from AI servers [4] Prepared Dishes - The State Council's Food Safety Office is drafting national standards for prepared dishes and will solicit public opinions soon, aiming to enhance consumer rights and promote industry development [5] - Prepared dishes are gaining popularity, especially among younger consumers, due to their convenience and ability to meet diverse culinary needs, leading to significant growth opportunities in the market [5] AI Chips - Alibaba Group plans to support its chip company Pingtouge for independent listing, reflecting its strategic focus on the semiconductor sector [6] - Pingtouge has made significant advancements in AI processing technology, with its products already integrated into major data centers, indicating its growing commercial value [6] General Industry News - The Chinese government is set to build a computing power scale of around 200,000 P by 2027, indicating a significant investment in computing infrastructure [8] - The domestic satellite constellation applications are expected to peak in the next decade, with China planning to launch over 20,300 satellites [8]

Core Viewpoint - Yangtianhe Pharmacy has announced the termination of its cooperation with certain O2O platforms, highlighting the challenges faced by retail pharmacies in the current O2O business environment [2][4]. Group 1: Company Actions - Yangtianhe's decision to withdraw from O2O platforms was publicly announced by its regional manager and later confirmed by the vice president, specifically targeting the JD O2O platform [2]. - The company emphasizes that it does not oppose innovation or the e-commerce model but is against the monopolistic rules set by platforms [2][3]. - Yangtianhe currently operates over 4,000 stores across 19 provinces in China, with its franchise model at the core of its business [2]. Group 2: Industry Challenges - Retail pharmacies are experiencing a loss of operational autonomy due to high commission rates and competitive pressures from O2O platforms [3][4]. - The average commission rate charged by platforms can reach 15%, which is higher than the maximum VAT rate for retail pharmacies, significantly squeezing profit margins [3][4]. - Delivery costs for O2O services are often higher than traditional B2C models, further impacting profitability for pharmacies [3][4]. Group 3: Market Trends - The O2O pharmaceutical market in China reached 29.1 billion yuan in August 2025, with a year-on-year growth of 29.6%, indicating a strong market demand despite challenges [4]. - Some industry experts believe that the O2O model will continue to thrive due to changing consumer habits and the integration of online medical insurance payment systems [4][5]. - The trend suggests that O2O business will increasingly concentrate among leading companies, creating a "stronger stronger" market dynamic [6]. Group 4: Recommendations for Improvement - Experts suggest that e-commerce platforms should lower commission rates and improve transparency in their fee structures to support retail pharmacies [8][9]. - Retail pharmacies are encouraged to enhance their operational capabilities, including maintaining a diverse product inventory and optimizing store layouts to meet consumer demand [9][10]. - The future of retail pharmacies may involve more specialized operations focusing on O2O, private traffic management, and regional distribution services [10].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The retail pharmacy industry is undergoing accelerated consolidation, with a significant reduction in the number of stores, leading to increased concentration benefiting leading players [4][15] - The number of retail pharmacies in China has decreased by nearly 20,000 since the fourth quarter of 2024, with a net reduction of 8,800 stores in the third quarter of 2025 alone [15][21] - Leading pharmacies are expected to see profit margins improve in 2026 due to operational optimizations and cost control measures [5][21] - The innovation drug sector is currently in a correction phase, but the maturation of clinical data is expected to drive future market performance [7][25] - The medical device sector is showing signs of recovery, with leading companies reporting improved performance in the third quarter of 2025 [29][30] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 2.06% in the last week of December 2025, underperforming the CSI 300 index by 1.47 percentage points [6][22] - The retail pharmacy sector experienced a decline of 4.11% during the same period [22] Retail Pharmacy Insights - The retail pharmacy industry is seeing a rapid exit of smaller players, with a focus on consolidating market share among leading pharmacies [15][37] - The implementation of drug traceability codes is expected to further increase industry concentration by raising operational costs for smaller pharmacies [20] Innovation Drug Sector - The innovation drug sector is experiencing a correction, but the maturation of clinical data is anticipated to be a key driver for future performance [7][25] - Companies with stable business development (BD) expectations are recommended for investment, including Innovent Biologics and 3SBio [26] Medical Device Sector - The medical device industry is expected to benefit from improved procurement processes and a reduction in the pressure from centralized procurement [29][30] - Leading companies are showing signs of recovery, with Q3 performance improving compared to earlier in the year [29] Traditional Chinese Medicine - The traditional Chinese medicine sector is under pressure but is expected to benefit from policies favoring essential medicines and inventory clearance [34][36]

Core Viewpoint - The company currently does not have a dedicated beauty division but has established a non-pharmaceutical division that includes beauty products [1] Group 1 - An investor inquired about the possibility of setting up a dedicated beauty division for online marketing and live streaming [1] - The company responded that its organizational structure does not currently include a beauty division [1] - The non-pharmaceutical division covers the beauty business [1]

Core Viewpoint - CVS Health has provided an optimistic earnings outlook for 2026, indicating that its transformation plan is progressing well, with expected profits exceeding Wall Street expectations and the company's own targets for the current year [1] Group 1: Earnings Guidance - CVS Health expects adjusted earnings per share for 2026 to be in the range of $7.00 to $7.20, with the average analyst expectation at $7.16 [1] - The company has raised its 2025 adjusted earnings per share forecast from $6.55 to $6.65 to a new range of $6.60 to $6.70 [1] Group 2: Revenue Expectations - CVS Health anticipates total revenue for 2026 to be at least $400 billion, which is below the average analyst expectation of $419.26 billion [1] Group 3: Business Performance - The CFO of CVS Health, Brian Newman, stated that all business segments experienced significant growth in 2025, and the company expects another year of strong profit growth in 2026 [1]

Group 1 - The upcoming removal of the tax exemption for contraceptives in 2026 will significantly increase costs for manufacturers, potentially raising prices by over 15% due to a 13% VAT on production costs [1] - The change in tax policy reflects a shift in China's population strategy, moving from controlling birth rates to encouraging them, as evidenced by the introduction of a tax exemption for marriage introduction services [2] - The financial impact on companies with annual sales exceeding 100 million yuan could be substantial, leading to a potential re-evaluation of financial statements due to the sudden increase in tax burdens [1] Group 2 - The tax reform is part of a broader demographic strategy, linking the price fluctuations of contraceptives to macroeconomic policies, thus involving consumers in a larger societal change [2] - The historical context of the tax exemption for contraceptives illustrates the evolution of China's population policies, transitioning from quantity control to quality enhancement [2] - Companies may need to adjust their supply chain costs in response to consumer behavior shifting towards cheaper brands, which could lead to market segmentation [1]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]